Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
507 participants
INTERVENTIONAL
2013-06-10
2019-06-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to compare such early intensive medical management with usual care in high-risk patients after discharge.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient
NCT01834833
Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients
NCT01529463
Outcome of Discharged HFmrEF Patients
NCT05240118
Risk Factors In Heart Failure Patients With Preserved Ejection Fraction
NCT06487468
Teach-Back Discharge Education to Improve Self-Care and Reduce 30-Day Readmissions in Heart Failure Patients
NCT07280208
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Control group: usual disease management according to guidelines and including first medical consultation and biological test within the 4-week time following discharge.
* Active group: consultations with HF specialist including biological test at weeks 1, 2 and 4 are planned in addition to usual management.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intensive disease management
Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
Natriuretic peptides levels to J7 and J14
Consultations specialized to J7 and J14
Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
Phone calls in 6 months and 12 months
Natriuretic peptides levels at 6 months
Consultation with the general doctor or the cardiologist to J30 with blood results
usual disease management
usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
Phone calls in 6 months and 12 months
Natriuretic peptides levels at 6 months
Consultation with the general doctor or the cardiologist to J30 with blood results
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Natriuretic peptides levels to J7 and J14
Consultations specialized to J7 and J14
Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
Phone calls in 6 months and 12 months
Natriuretic peptides levels at 6 months
Consultation with the general doctor or the cardiologist to J30 with blood results
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* consent signed
* Acute or decompensated heart failure with one or more of following criteria::
* Discharge BNP \> 350 pg/ml or NTproBNP \> 2200 pg/ml
* Discharge serum creatinine ≥ 180µM
* Discharge systolic blood pressure ≤ 110mmHg
* Previous hospitalisation for acute heart failure \< 6 months
Exclusion Criteria
* acute myocarditis,
* isolated right HF,
* transient HF,
* planned cardiac surgery,
* high risk of short-term non-cardiac death,
* planned management within rehabilitation center/HF clinic at discharge
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LOGEART Damien, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Lariboisiere Hospital, APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Cardiologie - Hopital Lariboisière
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P110128
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.